false
0001692415
0001692415
2024-05-09
2024-05-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): May 9, 2024
CO-DIAGNOSTICS,
INC.
(Exact
name of small business issuer as specified in its charter)
Utah |
|
1-38148 |
|
46-2609363 |
(State
or other jurisdiction of |
|
(Commission |
|
(IRS
Employer |
incorporation
or organization) |
|
File
Number) |
|
Identification
Number) |
2401
S. Foothill Drive, Suite D, Salt Lake City, Utah 84109
(Address
of principal executive offices)
(801)
438-1036
(Issuer’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
CODX |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
May 9, 2024, Co-Diagnostics, Inc. (the “Company”) issued a press release announcing financial results for its quarter ended
March 31, 2024. The full text of the press release, which includes information regarding the Company’s use of a non-GAAP financial
measure, is furnished as Exhibit 99.1 to this Form 8-K.
The
information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore,
the information contained in this Item 2.02 or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration
statement or other document filed pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference
in such filing.
Item
7.01. Regulation FD. Disclosure.
The
information set forth under Item 2.02 is incorporated by reference as if fully set forth herein.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
|
CO-DIAGNOSTICS,
INC. |
|
|
|
Date:
May 9, 2024 |
By: |
/s/
Brian Brown |
|
Name: |
Brian
Brown |
|
Title: |
Chief
Financial Officer
|
|
|
(Principal
Financial and Accounting Officer) |
Exhibit
99.1
Co-Diagnostics,
Inc. Reports First Quarter 2024 Financial Results
SALT
LAKE CITY, May 9, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Dx,” or the “Company”),
a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial
results for the quarter ended March 31, 2024.
First
Quarter 2024 Financial Results:
|
● |
Revenue
of $0.5 million, down from $0.6 million during the prior year. Grant revenue totaled $0.2 million while product revenue totaled $0.3
million |
|
● |
Operating
expenses of $10.5 million increased by 4.4% from the prior year due to an increase in research and development costs incurred for
the development of tests currently in our pipeline |
|
● |
Operating
loss of $10.3 million compared to operating loss of $10.0 million in Q1 2023 |
|
● |
Net
loss of $9.3 million, compared to net loss of $5.8 million in the prior year, representing a loss of $0.31 per fully diluted share,
compared to a loss of $0.20 per fully diluted share in the prior year |
|
● |
Adjusted
EBITDA loss of $8.4 million compared to $7.2 million in Q1 2023 |
|
● |
Cash,
cash equivalents, and marketable securities of $50.0 million as of March 31, 2024
|
First
Quarter and Recent 2024 Business Highlights:
|
● |
Appointed
Richard Abbott as President of Co-Diagnostics. Also appointed David Nielsen as Chief Operations Officer (COO), Christopher Thurston
as Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO) |
|
● |
Inaugurated
a new manufacturing facility in South Salt Lake to manufacture our patented Co-Primers® oligonucleotides, the Co-Dx™ PCR
Pro™ instrument, and test cups for the new Co-Dx PCR platform |
|
● |
Delivered
a keynote address at the 5th Annual MarketsandMarkets conference in London, which included an update of continued
expansion of the CoSara manufacturing facility in India to enable greater capacity for in-house manufacturing of reagents, equipment
and consumables, along with the ability to manufacture Co-Primers |
“We
are extremely encouraged by our first quarter progress and believe that we are well positioned to meet our 2024 goals,” said Dwight
Egan, Co-Diagnostics’ Chief Executive Officer. “Co-Diagnostics was pleased to announce the opening of our new manufacturing
facility in Salt Lake and continued facility expansion in India, which will soon enable in-house Co-Primers, instrument, and test manufacturing
at a low cost. We remain committed to delivering a 510(k) submission to the FDA for our new instrument and COVID-19 test kit in the near
future and driving development of our TB, multiplex respiratory, and HPV tests throughout the remainder of the year.”
“This
is an exciting time for Co-Diagnostics and we truly believe in the disruptive and unique nature of our new platform. We look forward
to beginning clinical evaluations for our multiplex test later this year and plan to provide updates on our new platform and pipeline
progress as they come,” said Brian Brown, Co-Diagnostics’ Chief Financial Officer.
Conference
Call and Webcast
Co-Diagnostics
will host a conference call and webcast at 4:30 p.m. EDT today to discuss its financial results with analysts and institutional investors.
The conference call and webcast will be available via:
Webcast:
ir.co-dx.com on the Events & Webcasts page
Conference
Call: 844-481-2661 (domestic) or 412-317-0652 (international)
The
call will be recorded and later made available on the Company’s website: https://co-dx.com.
*The
Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the
FDA and/or other regulatory bodies and is not yet available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently
under review by the FDA.
About
Co-Diagnostics, Inc.:
Co-Diagnostics,
Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.
The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules
(DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform
and to locate genetic markers for use in applications other than infectious disease.
Non-GAAP
Financial Measures:
This
press release contains adjusted EBITDA, which is a non-GAAP measure defined as net income excluding depreciation, amortization, income
tax (benefit) expense, net interest (income) expense, realized gains on investments, and stock-based compensation. The Company
believes that adjusted EBITDA provides useful information to management and investors relating to its results of operations. The Company’s
management uses this non-GAAP measure to compare the Company’s performance to that of prior periods for trend analyses, and for
budgeting and planning purposes. The Company believes that the use of adjusted EBITDA provides an additional tool for investors to use
in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other companies, many
of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics
used by management in its financial and operational decision-making.
Management
does not consider the non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The
principal limitation of the non-GAAP financial measure is that it excludes significant expenses that are required by GAAP to be recorded
in the Company’s financial statements. In order to compensate for these limitations, management presents the non-GAAP financial
measure together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but
should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of the net income, the most comparable
GAAP financial measure to adjusted EBITDA, is included at the end of this release. The Company urges investors to review the reconciliation
and not to rely on any single financial measure to evaluate the company’s business.
Forward-Looking
Statements:
This press release
contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,”
“expects,” “estimates,” “intends,” “may,” “plans,” “will”
and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they
exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this
release include statements that our expansion in India will soon enable in-house manufacturing at a low cost, our commitment to
deliver a 510(k) submission to the FDA for our new instrument and COVID-19 test kit in the near future, and our plan to begin
clinical evaluations for our multiplex test later this year . Forward-looking statements are subject to inherent uncertainties,
risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such
forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking
statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain
risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed
with the Securities and Exchange Commission (SEC) on March 14, 2024, and in our other filings with the SEC. The Company does not
undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may
be required by applicable securities laws.
Investor
Relations Contact:
Andrew
Benson
Head
of Investor Relations
+1
801-438-1036
investors@codiagnostics.com
CO-DIAGNOSTICS,
INC. AND SUBSIDIARIES
CONSOLIDATED
BALANCE SHEETS
(Unaudited)
| |
March 31, 2024 | | |
December 31, 2023 | |
Assets | |
| | | |
| | |
Current assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 23,099,251 | | |
$ | 14,916,878 | |
Marketable investment securities | |
| 26,864,435 | | |
| 43,631,510 | |
Accounts receivable, net | |
| 434,868 | | |
| 303,926 | |
Inventory, net | |
| 1,549,812 | | |
| 1,664,725 | |
Income taxes receivable | |
| - | | |
| 26,955 | |
Prepaid expenses and other current assets | |
| 1,750,467 | | |
| 1,597,114 | |
Total current assets | |
| 53,698,833 | | |
| 62,141,108 | |
Property and equipment, net | |
| 3,183,116 | | |
| 3,035,729 | |
Operating lease right-of-use asset | |
| 2,758,757 | | |
| 2,966,774 | |
Intangible assets, net | |
| 26,328,000 | | |
| 26,403,667 | |
Investment in joint venture | |
| 702,427 | | |
| 773,382 | |
Total assets | |
$ | 86,671,133 | | |
$ | 95,320,660 | |
Liabilities and stockholders’ equity | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable | |
$ | 2,027,607 | | |
$ | 1,482,109 | |
Accrued expenses | |
| 1,324,779 | | |
| 2,172,959 | |
Operating lease liability, current | |
| 859,912 | | |
| 838,387 | |
Contingent consideration liabilities, current | |
| 750,877 | | |
| 891,666 | |
Deferred revenue | |
| 306,477 | | |
| 362,449 | |
Total current liabilities | |
| 5,269,652 | | |
| 5,747,570 | |
Long-term liabilities | |
| | | |
| | |
Income taxes payable | |
| 679,018 | | |
| 659,186 | |
Operating lease liability | |
| 1,931,164 | | |
| 2,152,180 | |
Contingent consideration liabilities | |
| 438,638 | | |
| 748,109 | |
Total long-term liabilities | |
| 3,048,820 | | |
| 3,559,475 | |
Total liabilities | |
| 8,318,472 | | |
| 9,307,045 | |
Commitments and contingencies (Note 10) | |
| | | |
| | |
Stockholders’ equity | |
| | | |
| | |
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | |
| - | | |
| - | |
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,127,096 shares issued and 31,278,418 shares outstanding as of March 31, 2024 and 36,108,346 shares issued and 31,259,668 shares outstanding as of December 31, 2023 | |
| 36,127 | | |
| 36,108 | |
Treasury stock, at cost; 4,848,678 shares held as of March 31, 2024 and December 31, 2023, respectively | |
| (15,575,795 | ) | |
| (15,575,795 | ) |
Additional paid-in capital | |
| 98,379,651 | | |
| 96,808,436 | |
Accumulated other comprehensive income | |
| 226,555 | | |
| 146,700 | |
Accumulated earnings (deficit) | |
| (4,713,877 | ) | |
| 4,598,166 | |
Total stockholders’ equity | |
| 78,352,661 | | |
| 86,013,615 | |
Total liabilities and stockholders’ equity | |
$ | 86,671,133 | | |
$ | 95,320,660 | |
CO-DIAGNOSTICS,
INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
| |
Three Months Ended March 31, | |
| |
2024 | | |
2023 | |
Product revenue | |
$ | 252,745 | | |
$ | 601,957 | |
Grant revenue | |
| 215,109 | | |
| - | |
Total revenue | |
| 467,854 | | |
| 601,957 | |
Cost of revenue | |
| 234,505 | | |
| 502,241 | |
Gross profit | |
| 233,349 | | |
| 99,716 | |
Operating expenses | |
| | | |
| | |
Sales and marketing | |
| 1,563,682 | | |
| 1,706,331 | |
General and administrative | |
| 2,918,803 | | |
| 3,013,965 | |
Research and development | |
| 5,679,678 | | |
| 5,014,060 | |
Depreciation and amortization | |
| 330,573 | | |
| 316,010 | |
Total operating expenses | |
| 10,492,736 | | |
| 10,050,366 | |
Loss from operations | |
| (10,259,387 | ) | |
| (9,950,650 | ) |
Other income, net | |
| | | |
| | |
Interest income | |
| 362,733 | | |
| 202,372 | |
Realized gain on investments | |
| 228,070 | | |
| 418,082 | |
Gain on remeasurement of acquisition contingencies | |
| 450,260 | | |
| 1,037,672 | |
Gain (loss) on equity method investment in joint venture | |
| (70,955 | ) | |
| 277,322 | |
Total other income, net | |
| 970,108 | | |
| 1,935,448 | |
Loss before income taxes | |
| (9,289,279 | ) | |
| (8,015,202 | ) |
Income tax provision (benefit) | |
| 22,764 | | |
| (2,259,811 | ) |
Net loss | |
$ | (9,312,043 | ) | |
$ | (5,755,391 | ) |
Other comprehensive loss | |
| | | |
| | |
Change in net unrealized gains on marketable securities, net of tax | |
| 79,855 | | |
| 178,621 | |
Total other comprehensive income | |
$ | 79,855 | | |
$ | 178,621 | |
Comprehensive loss | |
$ | (9,232,188 | ) | |
$ | (5,576,770 | ) |
| |
| | | |
| | |
Loss per common share: | |
| | | |
| | |
Basic and diluted | |
$ | (0.31 | ) | |
$ | (0.20 | ) |
Weighted average shares outstanding: | |
| | | |
| | |
Basic and diluted | |
| 29,842,874 | | |
| 29,483,540 | |
CO-DIAGNOSTICS,
INC. AND SUBSIDIARIES
GAAP
AND NON-GAAP MEASURES
(Unaudited)
Reconciliation of net loss to adjusted EBITDA:
| |
Three Months Ended March 31, | |
| |
2024 | | |
2023 | |
Net loss | |
$ | (9,312,043 | ) | |
$ | (5,755,391 | ) |
Interest income | |
| (362,733 | ) | |
| (202,372 | ) |
Realized gain on investments | |
| (228,070 | ) | |
| (418,082 | ) |
Depreciation and amortization | |
| 330,573 | | |
| 316,010 | |
Change in fair value of contingent consideration | |
| (450,260 | ) | |
| (1,037,672 | ) |
Stock-based compensation expense | |
| 1,571,234 | | |
| 2,168,742 | |
Income tax provision (benefit) | |
| 22,764 | | |
| (2,259,811 | ) |
Adjusted EBITDA | |
$ | (8,428,535 | ) | |
$ | (7,188,576 | ) |
v3.24.1.u1
Cover
|
May 09, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
May 09, 2024
|
Entity File Number |
1-38148
|
Entity Registrant Name |
CO-DIAGNOSTICS,
INC
|
Entity Central Index Key |
0001692415
|
Entity Tax Identification Number |
46-2609363
|
Entity Incorporation, State or Country Code |
UT
|
Entity Address, Address Line One |
2401
S. Foothill Drive
|
Entity Address, Address Line Two |
Suite D
|
Entity Address, City or Town |
Salt Lake City
|
Entity Address, State or Province |
UT
|
Entity Address, Postal Zip Code |
84109
|
City Area Code |
(801)
|
Local Phone Number |
438-1036
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, par value $0.001 per share
|
Trading Symbol |
CODX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Co Diagnostics (NASDAQ:CODX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Co Diagnostics (NASDAQ:CODX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024